Effect of biological agents on B-lymphocyte subpopulations in patients with systemic lupus erythematosus
Objective: to evaluate the effect of different biological agents (BAs), including rituximab (RTM) and belimumab (BLM) combination therapy, on B-lymphocyte subpopulations during a follow-up of patients with systemic lupus erythematosus (SLE).Patients and methods. The investigation enrolled 64 patient...
Main Authors: | A. A. Mesnyankina, S. K. Solovyev, E. A. Aseeva, A. P. Aleksankin, E. N. Aleksandrova, E. L. Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2019-03-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/883 |
Similar Items
-
Sequential therapy with rituximab and belimumab in patients with systemic lupus erythematosus
by: A. A. Mesnyankina, et al.
Published: (2020-11-01) -
Anti-B cell therapy in patients with systemic lupus erythematosus
by: M. E. Tsanyan, et al.
Published: (2018-01-01) -
Treatment of patients with systemic lupus erythematosus without glucocorticoids – myth or reality?
by: S. K. Soloviev, et al.
Published: (2022-02-01) -
Genetically engineered biological agents in therapy for systemic lupus erythematosus
by: Elena Aleksandrovna Aseeva, et al.
Published: (2013-10-01) -
Experience in Rituximab Administration in Children with Systemic Lupus Erythematosus: a Retrospective Study of the Case Series
by: Mikhail M. Kostik, et al.
Published: (2016-08-01)